Trial Profile

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix Vaccination in Females Aged 9-25 Years in the US

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
Indications Cervical cancer; Human papillomavirus infections
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
30 Aug 2013 Planned end date changed from 1 Dec 2050 to 1 Jun 2014 as reported by ClinicalTrials.gov.
28 Sep 2012 Planned end date changed from 1 Oct 2014 to 1 Dec 2050 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com